Hostname: page-component-745bb68f8f-g4j75 Total loading time: 0 Render date: 2025-01-11T04:01:27.427Z Has data issue: false hasContentIssue false
  • English
  • Français

Is Lorazepam a Treatment for Neuroleptic Malignant Syndrome?

Published online by Cambridge University Press:  07 November 2014

Andrew Francis ,
Sanjay Chandragiri ,
Syed Rizvi ,
Monika Koch  and
Georgios Petrides
Get access Rights & Permissions [Opens in a new window]

Abstract

The authors assessed the ability of lorazepam and other benzodiazepines to affect the course of neuroleptic malignant syndrome (NMS). Records of inpatients who met both stringent research criteria and criteria under the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) (n=11) or DSM-IV criteria alone (n=5)for NMS were identified. All received lorazepam or related benzodiazepines within 24 hours of NMS onset or hospital admission. The records were reviewed for resolution of clinical signs NMS. Rigidity and fever abated within 24—48 hours, while secondary features of NMS were relieved within 64 hours. These results compared favorably with prior reports of 5-day to 10-day recovery periods. Benzodiazepine administration appeared to be well tolerated. Lorazepam and related benzodiazepines may reduce recovery time in NMS.

Type
Feature Articles
Information
CNS Spectrums , Volume 5 , Issue 7: Mechanisms and Presentations of Catatonia , July 2000 , pp. 54 - 57
Copyright
Copyright © Cambridge University Press 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Levenson, JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142:1137–1145.Google ScholarPubMed
2.Caroff, SN, Mann, SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77:185–202.CrossRefGoogle ScholarPubMed
3.Rosenberg, MR, Green, M. Neuroleptic malignant syndrome: review of response to therapy. Arch Intern Med. 1989;149:1927–1931.CrossRefGoogle ScholarPubMed
4.Sakkas, O, Davis, JM, Hua, J, et al.Pharmacotherapy of neuroleptic malignant syndrome. Psychiatr Ann. 1991;21:157–164.CrossRefGoogle Scholar
5.Rosebush, PI, Stewart, T, Mazurek, MF. The treatment of neuroleptic malignant syndrome: are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry. 1991;159:709–712.CrossRefGoogle ScholarPubMed
6.Miyaoka, H, Shishkura, K, Otsubo, T, et al.Diazepam-responsive neuroleptic malignant syndrome: a diagnostic subtype? Am J Psychiatry. 1997;153:882.Google Scholar
7.Lew, TY, Tollefson, G. Chlorpromazine-induced neuroleptic syndrome and its response to lorazepam. Biol Psychiatry. 1983;18:1441–1446.Google Scholar
8.Kontaxakis, VP, Christodoulou, GN, Markidis, MP, et al.Treatment of a mild form of neuroleptic malignant syndrome with oral diazepam. Acta Psychiatr Scand. 1988;78:396–398.CrossRefGoogle ScholarPubMed
9.Khaldarov, V. Benzodiazepines as treatment for neuroleptic malignant syndrome. Hospital Physician. 2000. In press.Google Scholar
10.Fink, M. Neuroleptic malignant syndrome and catatonia: one entity or two? Biol Psychiatry. 1996;39:1–4.CrossRefGoogle ScholarPubMed
11.Carroll, BT, Taylor, RE. The nondichotomy between lethal catatonia and neuroleptic malignant syndrome. J Clin Psychopharmacol. 1997;17:235–238.CrossRefGoogle ScholarPubMed
12.White, DAC. Catatonia and the neuroleptic malignant syndrome—a single entity? Br J Psychiatry. 1992;161:558–560.CrossRefGoogle ScholarPubMed
13.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington DC: American Psychiatric Press; 1994.Google Scholar
14.Kaplan, H, Sadock, BJ, Grebb, JE, eds. Synopsis of Psychiatry. Baltimore, Md: Williams and Wilkins; 1994:913.Google Scholar
15.Addonizio, G, Susman, VL, Roth, SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry. 1987;22:1004–1020.CrossRefGoogle ScholarPubMed
16.Rosebush, P, Stewart, T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989;146:717–725.Google ScholarPubMed
17.Caroff, SN, Mann, SC. Neuroleptic malignant syndrome. Psychopharmacol Bull. 1988;24:25–29.Google ScholarPubMed
18.Holloman, LC, Marder, SC. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health System Pharmacists. 1997;54:2461–2477.CrossRefGoogle ScholarPubMed
19.Koch, M, Chandragiri, S, Rizvi, S, et al.Catatonic signs in neuroleptic malignant syndrome. Compr Psychiaty. 2000;41:73–75.CrossRefGoogle ScholarPubMed
20.Francis, A, Divadeenam, K, Petrides, G. Advances in the diagnosis and treatment of catatonia. Convuls Ther. 1996;12:259–261.Google ScholarPubMed
21.Fricchione, G. Catatonia: a new indication for benzodiazepines? Biol Psychiatry. 1989;26:761–765.CrossRefGoogle ScholarPubMed
22.Rosebush, PI, Hildebrand, AM, Furlong, BG, et al.Catatonic syndrome in a general psychiatric population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry. 1990;51:357–362.Google Scholar
23.Fricchione, GL, Cassem, NC, Hooberman, D, et al.Intravenous lorazepam in neuroleptic-induced catatonia. J Clin Psychopharmacol. 1983;3:338–342.CrossRefGoogle ScholarPubMed
24.Caroff, SN. The neuroleptic malignant syndrome. J Clin Psychiatry. 1980;41:79–83.Google ScholarPubMed
25.Kurlan, R, Hamill, R, Shoulson, I. Neuroleptic malignant syndrome. Clin Neuropharmacol. 1984;7:109–120.CrossRefGoogle ScholarPubMed
26.Sachdev, A, Munitz, H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand. 1986;73:337–347.Google Scholar